PCSA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 118944 min ago

@ $2.43

Wydano: 12 vas. 2024 @ 22:26

Zwrot: -10.70%

Poprzedni sygnał: vas. 6 - 21:26

Poprzedni sygnał: Sprzedaż

Zwrot: 0.00 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Dzisiejszy wolumen	88 569.00
Średni wolumen	1.50M
Kapitalizacja rynkowa	6.20M
EPS	$0 ( 2024-04-04 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.0210 (0.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.35
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Wolumen Korelacja

Długi: 0.04 (neutral)

Krótki: -0.09 (neutral)

Signal:(43.019) Neutral

Processa Pharmaceuticals, Korelacja

10 Najbardziej pozytywne korelacje
CNSP	0.946
AGIL	0.943
TANH	0.942
MOTS	0.939
UXIN	0.934
AYLA	0.931
KXIN	0.93
HYW	0.928
TCBP	0.921
BJDX	0.92

10 Najbardziej negatywne korelacje
TVTY	-0.946
STTK	-0.943
STEP	-0.925
MBINO	-0.922
IMPP	-0.916
ALOT	-0.915
MTCR	-0.914
ORTX	-0.913
CCRC	-0.897
SGII	-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Processa Pharmaceuticals, Korelacja - Waluta/Towar

-0.69
( moderate negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.39
( neutral )

-0.07
( neutral )

Processa Pharmaceuticals, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2023
Przychody:	$0
Zysk brutto:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2022
Przychody:	$0
Zysk brutto:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.